NCT05794516

A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants

A Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB004 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Zenas BioPharma (USA), LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of single-ascending doses of ZB004.

Detailed description

Up to approximately 40 healthy volunteers across 5 cohorts randomized to receive ZB004 or placebo as single doses.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ZB004	ZB004 single doses administered subcutaneously as solution
DRUG	Placebo	Placebo single doses administered subcutaneously as solution

Timeline

• Start date: 2023-06-19
• Primary completion: 2024-03-21
• Completion: 2024-03-21
• First posted: 2023-04-03
• Last updated: 2025-04-13

Locations

1 site across 1 country: New Zealand